MAR 15, 2017 5:34 PM PDT

Potential new Test and Treatment for Preterm Birth Identified

WRITTEN BY: Carmen Leitch

Preterm birth is a widespread health problem; The World Health Organization estimates that around 15 million babies are born preterm every year, and that number is only increasing. There are dire effects from preterm birth as well; the resulting complications are the leading cause of death of children under the age of five. While some could be prevented with better medical care, many times it is a total mystery as to why it happens. Researchers have now gotten some insight into how inflammation might be a cause. They found a molecule driving that inflammation, and it likely plays a role in why mild prenatal infections can trigger preterm birth. This work could aid in the development of a clinical test for preterm birth. The findings have been reported in The Journal of Clinical Investigation Insight (JCI Insight).

Investigators at Cincinnati Children's Hospital Medical Center, determined that a receptor that aids in immune system regulation, the type I Interferon receptor (IFNAR) influences preterm birth caused by infection. When pregnant women are subclinically, or in a way that doesn't require a visit to a clinic, sickened by viral or bacterial infections, the problem begins. INFAR receptors on blood immune cells bind to an immune protein, type I Interferon (type I IFN), thereby stimulating the production of pro-inflammatory cytokines during secondary inflammatory challenge. That's the mechanism proposed to underlie preterm birth, delivery before 37 completed weeks of gestation.

"Preterm birth is a leading worldwide cause of illness and death in infants. The biological processes linked to the ability of pathogens to help cause preterm birth have been unknown," explained the lead investigator of the work, Senad Divanovic, PhD, a member of Division of Immunobiology. "Identifying active type I IFN/IFNAR as an immunological driver provides an actionable biomarker and potential therapeutic target for reducing preterm birth risk in these circumstances."

It is known that inflammation caused by microbial infection influences preterm birth, but mysteriously, only a subset of microbes is responsible for the problem. Because every microbe found in maternal and fetal tissue doesn't result in infection, the researchers suggested that underlying biological triggers cause the differences. To find out more about those triggers, the investigators used a mouse model of preterm birth as well as samples from monkeys and humans zeroing in on type I IFN/IFNAR.

The scientists took the time to confirm that the type I interferon signaling is very similar in their models. When they assayed the role of type I IFN/IFNAR in a primary, subclinical viral flu infection before a secondary bacterial inflammation, they found that the primary viral infection triggered activation of type I IFN/IFNAR. That subsequently caused an overload of pro-inflammatory cytokine production. 

Importantly, when type I IFN, IFNAR or IL-6 were ablated from a mouse model, or antibodies that neutralized those molecules were administered, the animals no longer experienced preterm birth.

Divanovic noted that the research is continuing; the investigators are now trying to find the location where pro-inflammatory cells and pathways first become sensitized. Additionally, they want to broaden their analysis to gain a deeper understanding of the role of type I IFN during infections, var and how differences in that process influence the susceptibility to preterm birth. They also want to find out more about using a targeted inhibition of type I IFN/IFNAR to mitigate the risk of preterm birth.

 

In this recent video, the NIH has found that transvaginal cervical length and fetal fibronectin tests were not reliable indicators of preterm birth among first-time pregnancies.

 

Sources: ScienceDaily via Cincinnati Children's Hospital Medical Center, JCI Insight

About the Author
  • Experienced research scientist and technical expert with authorships on over 30 peer-reviewed publications, traveler to over 70 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
MAY 18, 2021
Clinical & Molecular DX
A Crystal Ball for Predicting Labor Day
MAY 18, 2021
A Crystal Ball for Predicting Labor Day
Expectant mothers may no longer have to be caught off guard—researchers have identified biomarkers in the blood th ...
JUN 10, 2021
Clinical & Molecular DX
Algorithm Flags High Risk of Pancreatic Cancer
JUN 10, 2021
Algorithm Flags High Risk of Pancreatic Cancer
In 2021, over 60,000 individuals in the U.S. alone will be diagnosed with pancreatic cancer. Researchers are turning to ...
JUN 16, 2021
Clinical & Molecular DX
Rapid Screening Tool Provides Insights on Brain Health
JUN 16, 2021
Rapid Screening Tool Provides Insights on Brain Health
Scientists at King’s College London have identified a single biomarker that can be used to diagnose a range of neu ...
JUL 15, 2021
Clinical & Molecular DX
Childhood Lead Exposure Influences Personality in Adulthood
JUL 15, 2021
Childhood Lead Exposure Influences Personality in Adulthood
Exposure to toxic chemicals in childhood could have unlikely effects on personality, and behavioral traits in adulthood, ...
SEP 09, 2021
Clinical & Molecular DX
A Drug Test for Synthetic Cannabis Use
SEP 09, 2021
A Drug Test for Synthetic Cannabis Use
Designer drugs are synthetic analogs of prohibited substances such as cocaine and LSD made in clandestine laboratories a ...
SEP 20, 2021
Cancer
An Established Ovarian Cancer Antigen Presents a Promising Therapeutic Target
SEP 20, 2021
An Established Ovarian Cancer Antigen Presents a Promising Therapeutic Target
For the past several decades, cancer antigen 125 (CA 125), a protein located on the surface of ovarian cancer cells, has ...
Loading Comments...